echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > JEM: The development of a new mouse model may be the key to developing better HIV therapies

    JEM: The development of a new mouse model may be the key to developing better HIV therapies

    • Last Update: 2021-06-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    May 28, 2021/Bio Valley BIOON/---Ordinary mice cannot be infected with HIV, and previous HIV mouse models used mice carrying human stem cells or CD4 T cells, of which human CD4 T cells are a type of Immune cells that can infect HIV
    .


    But these models are often of limited utility, because human cells will quickly see the mouse host’s tissues as "foreign" and attack them, causing the mice to become seriously ill


    In a new study, American researchers have developed a unique preclinical mouse model
    .


    In order to prevent mouse tissues from being attacked, a subset of human CD4 T cells carried by this model basically excludes cells that would attack mouse tissues


    These authors anticipate that this will become a valuable and widely used tool to study the basic science of HIV infection and accelerate the development of better therapies
    .


    This new mouse model is part of an extensive effort to develop and test cell therapies against HIV infection


    These authors found in this study that the problem of cell attacking the host previously found in mouse models is mainly caused by so-called "naïve" CD4 cells
    .


    These are human CD4 cells that have not yet come into contact with the target, and apparently include a cell population capable of attacking multiple mouse proteins


    These authors observed that these human memory CD4 cells can also be infected and killed by HIV, and can also be protected by standard anti-HIV drugs, basically in the same way as in humans
    .


    Therefore, they discovered that these mice--what they call participant-derived xenograft (PDX) mice--can be used as a viable model for studying long-term HIV infection


    Finally, the authors used this new mouse model to study a prospective new T cell-based therapy that is very similar to the CAR-T cell therapy for cancer that is now being tested
    .


    They implanted memory CD4 T cells from human donors into mice to allow HIV infection, and then after the infection was established, they injected another type of human T cells (CD8 T cells, also called killer T cells) into the mice.


    These killer T cells and memory CD4 T cells come from the same human donor and can recognize the fragile structures on HIV, so they will attack the virus when they find the virus in mice
    .


    In order to improve the effectiveness of killer T cells, these authors stimulated them with a T cell stimulating protein called IL-15


    This treatment method effectively suppressed HIV in mice
    .


    Although, as often seen in human cases, this virus has evolved to eventually evade the recognition of killer T cells, the ease of use of this mouse model allows these authors to monitor and study these long-term infections and viruses in detail.


    Reference materials:

    Reference materials:

    Chase D.
    McCann et al.
    A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies.
    Journal of Experimental Medicine, 2021, doi:10.
    1084/jem.
    20201908.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.